NDA 020237 · Advanz Pharma
Salagen
Pilocarpine Hydrochloride · Oral
Priority reviewOrphanLast checked: Nov 19, 2026Latest source record: Sep 10, 2015 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1994
Mar 22, 1994
Approved uses
2
Original approval plus efficacy supplements
Registered trials
57
21 Phase 3, 2 recruiting
FAERS reports
2,485
1,537 serious, 101 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jan 23, 2026.
INDICATIONS AND USAGE Pilocarpine Hydrochloride Tablets are indicated for 1) the treatment of symptoms of dry mouth from salivary gland hypofunction caused by radiotherapy for cancer of the head and neck; and 2) the treatment of symptoms of dry mouth in patients with Sjogren's Syndrome.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Feb 11, 1998 Supplement 7 · Efficacy ReviewLetter
- Mar 22, 1994 Original approval · Type 3 - New Dosage Form · priority review
2 products under this application
- SALAGEN · PILOCARPINE HYDROCHLORIDE 5MG · TABLET, ORAL · Prescription · TE AB
- SALAGEN · PILOCARPINE HYDROCHLORIDE 7.5MG · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Pilocarpine" as an intervention, any sponsor and status, largest first.
- A Phase 3 Efficacy Study of Pilocarpine HCl Ophthalmic Solution (AGN-190584) in Participants With PresbyopiaPivotal-lookingCompleted
AllerganAbbVie (ABBV)
NCT03857542 · 427 participants · Start Mar 1, 2019 · Primary completion Sep 10, 2020
Drug: Pilocarpine HCl Ophthalmic Solution · For: Presbyopia
Sites: Dothan, Alabama; Prescott, Arizona; Sun City, Arizona · 35 sites in all
- Clinical Study to Assess the Efficacy and Safety of THVD-201 in Patients With OABPivotal-lookingCompleted
SK Chemicals Co., Ltd.Industry
NCT02485067 · 384 participants · Start Jan 2015 · Primary completion Jul 2016
Drug: THVD-201; Placebo(For THVD-201) and 2 more · For: Overactive Bladder
Sites: Busan, South Korea; Cheonan, South Korea; Gwangju, South Korea · 16 sites in all
- Safety and Efficacy of Nyxol Eye Drops as a Single Agent and With Adjunctive Low-Dose Pilocarpine Eye Drops in Subjects With PresbyopiaPivotal-lookingCompleted
Opus Genetics, IncIndustry
NCT05646719 · 333 participants · Start Dec 22, 2022 · Primary completion Oct 11, 2023
Drug: Phentolamine Opthalmic Solution 0.75%; Low dose pilocarpine · For: Presbyopia
Sites: Phoenix, Arizona; Azusa, California; Newport Beach, California · 26 sites in all
- Safety and Efficacy Study of Pilocarpine HCl Ophthalmic Solution in Participants With PresbyopiaPivotal-lookingStatus unknown
CSPC Ouyi Pharmaceutical Co., Ltd.Industry
NCT06451666 · 330 participants (planned) · Start Jun 30, 2024 · Primary completion Nov 30, 2025
Drug: Pilocarpine HCl Ophthalmic Solution; Vehicle · For: Presbyopia
- Efficacy Study of Pilocarpine HCl Ophthalmic Solution (AGN-190584) in Participants With PresbyopiaPivotal-lookingCompleted
AllerganAbbVie (ABBV)
NCT03804268 · 323 participants · Start Dec 21, 2018 · Primary completion Oct 31, 2019
Drug: Pilocarpine HCl Ophthalmic Solution · For: Presbyopia
Sites: Chandler, Arizona; Scottsdale, Arizona; Beverly Hills, California · 36 sites in all
- An Evaluation of the Efficacy and Safety of CSF-1 in the Temporary Correction of Presbyopia (NEAR-1)Pivotal-lookingCompleted
Orasis Pharmaceuticals Ltd.Industry
NCT04599933 · 309 participants · Start Oct 18, 2020 · Primary completion Feb 11, 2022
Drug: CSF-1; Vehicle · For: Presbyopia
Sites: Sun City, Arizona; Glendale, California; Los Angeles, California · 17 sites in all
- An Evaluation of the Efficacy and Safety of CSF-1 in the Temporary Correction of Presbyopia (NEAR-2)Pivotal-lookingCompleted
Orasis Pharmaceuticals Ltd.Industry
NCT04599972 · 304 participants · Start Oct 26, 2020 · Primary completion Jan 21, 2022
Drug: CSF-1; Vehicle · For: Presbyopia
Sites: Chandler, Arizona; Mesa, Arizona; Phoenix, Arizona · 18 sites in all
- The International Collaborative Exfoliation Syndrome Treatment StudyPivotal-lookingStatus unknown
The New York Eye & Ear InfirmaryAcademic, hospital or other
NCT00804115 · 277 participants · Start Aug 2000 · Primary completion Sep 2007
Drug: Latanoprost with Pilocarpine vs Timolol or Cosopt · For: Exfoliation Syndrome; Glaucoma; Ocular Hypertension
Sites: New York, New York
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective223
- headache199
- pain195
- fatigue187
- nausea174
- off label use154
- dyspnoea149
- arthralgia141
- dizziness130
- fall127
- diarrhoea124
- cough117
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 60 |
| 2005 | 62 |
| 2006 | 38 |
| 2007 | 34 |
| 2008 | 51 |
| 2009 | 73 |
| 2010 | 88 |
| 2011 | 55 |
| 2012 | 68 |
| 2013 | 77 |
| 2014 | 77 |
| 2015 | 100 |
| 2016 | 105 |
| 2017 | 123 |
| 2018 | 112 |
| 2019 | 141 |
| 2020 | 167 |
| 2021 | 140 |
| 2022 | 176 |
| 2023 | 160 |
| 2024 | 178 |
| 2025 | 228 |
| 2026 | 172 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Salagen (Pilocarpine HCl)
2024 spending
$31K
Beneficiaries
38
136 claims
Per beneficiary
$822
$1.74 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $65,095 |
| 2021 | $35,249 |
| 2022 | $34,160 |
| 2023 | $42,840 |
| 2024 | $31,254 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Neurosteroids and Seizure Activity.
Miziak B, Chrościska-Krawczyk M, Czuczwar SJ · Front Endocrinol (Lausanne) 2020 · Research Support, Non-U.S. Gov't, Systematic Review
- Safety and Efficacy of AGN-190584 in Individuals With Presbyopia: The GEMINI 1 Phase 3 Randomized Clinical Trial.
Waring GO, Price FW, Wirta D, et al. · JAMA Ophthalmol 2022 · Clinical Trial, Phase III, Randomized Controlled Trial
- Impact of presbyopia treatment pilocarpine hydrochloride 1.25% on night-driving performance.
Waring GO, Brujic M, McGee S, et al. · Clin Exp Optom 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
- Miotics in closed-angle glaucoma.
Ganias F, Mapstone R · Br J Ophthalmol 1975 · Clinical Trial, Comparative Study
- Pupillometry in Chagas disease.
Vargas D, Castro C · Arq Bras Oftalmol 2018 · Clinical Trial
- Two decades of research towards a potential first anti-epileptic drug.
Benassi SK, Alves JGSM, Guidoreni CG, et al. · Seizure 2021 · Randomized Controlled Trial
Sponsor: Advanz Pharma
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.